REPORTS

Let’s Pullulate and Expand Your Business

Autoimmune Drugs Market - Global Professional Analysis and Forecast to 2026

Oct 18, 2019  |  180 PAGES  |  REPORT CODE: CMM216663
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Autoimmune Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 9.1% during the forecast period.

This report presents the market size and development trends by detailing the Autoimmune Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Autoimmune Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Autoimmune Drugs industry and will help you to build a panoramic view of the industrial development.

Autoimmune Drugs Market, By Type:

  • Rheumatoid Arthritis (RA)

  • Multiple Sclerosis (MS)

  • Psoriasis

  • Inflammatory Bowel Disease (IBD)

  • Ankylosing Spondylitis (AS)

  • Systemic Lupus Erythematosus (SLE)

Autoimmune Drugs Market, By Application:

  • Hospital

  • Clinic

Some of the leading players are as follows:

  • Amgen

  • Sanofi

  • Boehringer Ingelheim

  • Biogen

  • Eli Lilly

  • Can-Fite BioPharma

  • Takeda Pharmaceuticals

  • Johnson & Johnson

  • F. Hoffmann-La Roche

  • Lexicon Pharmaceuticals

  • Eisai

  • KaloBios Pharmaceuticals

  • Novartis

  • Acorda Therapeutics

  • Pfizer

  • Merck

  • Vertex Pharmaceuticals

  • GSK

  • AbbVie

  • Antares Pharma

  • AstraZeneca

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Autoimmune Drugs Market: Technology Type Analysis

  • 4.1 Autoimmune Drugs Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Autoimmune Drugs Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Rheumatoid Arthritis (RA)

    • 4.3.2 Multiple Sclerosis (MS)

    • 4.3.3 Psoriasis

    • 4.3.4 Inflammatory Bowel Disease (IBD)

    • 4.3.5 Ankylosing Spondylitis (AS)

    • 4.3.6 Systemic Lupus Erythematosus (SLE)

5 Autoimmune Drugs Market: Product Analysis

  • 5.1 Autoimmune Drugs Product Market Share Analysis, 2018 & 2026

  • 5.2 Autoimmune Drugs Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Autoimmune Drugs Market: Application Analysis

  • 6.1 Autoimmune Drugs Application Market Share Analysis, 2018 & 2026

  • 6.2 Autoimmune Drugs Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Hospital

    • 6.3.2 Clinic

7 Autoimmune Drugs Market: Regional Analysis

  • 7.1 Autoimmune Drugs Regional Market Share Analysis, 2018 & 2026

  • 7.2 Autoimmune Drugs Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Amgen

    • 9.1.1 Amgen Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Sanofi

    • 9.2.1 Sanofi Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Boehringer Ingelheim

    • 9.3.1 Boehringer Ingelheim Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Biogen

    • 9.4.1 Biogen Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Eli Lilly

    • 9.5.1 Eli Lilly Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Can-Fite BioPharma

    • 9.6.1 Can-Fite BioPharma Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Takeda Pharmaceuticals

    • 9.7.1 Takeda Pharmaceuticals Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Johnson & Johnson

    • 9.8.1 Johnson & Johnson Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 F. Hoffmann-La Roche

    • 9.9.1 F. Hoffmann-La Roche Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Lexicon Pharmaceuticals

    • 9.10.1 Lexicon Pharmaceuticals Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Eisai

    • 9.11.1 Eisai Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 KaloBios Pharmaceuticals

    • 9.12.1 KaloBios Pharmaceuticals Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 Novartis

    • 9.13.1 Novartis Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 Acorda Therapeutics

    • 9.14.1 Acorda Therapeutics Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 Pfizer

    • 9.15.1 Pfizer Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

  • 9.16 Merck

    • 9.16.1 Merck Company overview

    • 9.16.2 Financial performance

    • 9.16.3 Product benchmarking

    • 9.16.4 Strategic initiatives

    • 9.16.5 SWOT analysis

  • 9.17 Vertex Pharmaceuticals

    • 9.17.1 Vertex Pharmaceuticals Company overview

    • 9.17.2 Financial performance

    • 9.17.3 Product benchmarking

    • 9.17.4 Strategic initiatives

    • 9.17.5 SWOT analysis

  • 9.18 GSK

    • 9.18.1 GSK Company overview

    • 9.18.2 Financial performance

    • 9.18.3 Product benchmarking

    • 9.18.4 Strategic initiatives

    • 9.18.5 SWOT analysis

  • 9.19 AbbVie

    • 9.19.1 AbbVie Company overview

    • 9.19.2 Financial performance

    • 9.19.3 Product benchmarking

    • 9.19.4 Strategic initiatives

    • 9.19.5 SWOT analysis

  • 9.20 Antares Pharma

    • 9.20.1 Antares Pharma Company overview

    • 9.20.2 Financial performance

    • 9.20.3 Product benchmarking

    • 9.20.4 Strategic initiatives

    • 9.20.5 SWOT analysis

  • 9.21 AstraZeneca

    • 9.21.1 AstraZeneca Company overview

    • 9.21.2 Financial performance

    • 9.21.3 Product benchmarking

    • 9.21.4 Strategic initiatives

    • 9.21.5 SWOT analysis

 

The List of Tables and Figures (Totals 103 Figures and 155 Tables)

  • Figure Rheumatoid Arthritis (RA) Autoimmune Drugs market, 2015 - 2026 (USD Million)

  • Figure Multiple Sclerosis (MS) Autoimmune Drugs market, 2015 - 2026 (USD Million)

  • Figure Psoriasis Autoimmune Drugs market, 2015 - 2026 (USD Million)

  • Figure Inflammatory Bowel Disease (IBD) Autoimmune Drugs market, 2015 - 2026 (USD Million)

  • Figure Ankylosing Spondylitis (AS) Autoimmune Drugs market, 2015 - 2026 (USD Million)

  • Figure Systemic Lupus Erythematosus (SLE) Autoimmune Drugs market, 2015 - 2026 (USD Million)

  • Figure Hospital market, 2015 - 2026 (USD Million)

  • Figure Clinic market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Autoimmune Drugs market, by country, 2015 - 2026 (USD Million)

  • Table North America Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table North America Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table North America Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Canada Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Canada Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Europe Autoimmune Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Europe Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Europe Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Europe Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Germany Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Germany Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table France Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table France Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Italy Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Italy Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Spain Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Spain Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Autoimmune Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table China Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table China Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Japan Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Japan Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table India Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table India Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Autoimmune Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table MEA Autoimmune Drugs market, by country, 2015 - 2026 (USD Million)

  • Table MEA Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table MEA Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table MEA Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Autoimmune Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Autoimmune Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Autoimmune Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Amgen Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sanofi Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Boehringer Ingelheim Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Biogen Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Eli Lilly Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Can-Fite BioPharma Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Takeda Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Johnson & Johnson Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table F. Hoffmann-La Roche Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Lexicon Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Eisai Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table KaloBios Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novartis Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Acorda Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Merck Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Vertex Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table GSK Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AbbVie Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Antares Pharma Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$4840
$9680
BUY NOWClick MeBUY NOW
top